SCHEMBL1703595

SCHEMBL1703595

Cc1cccc(NC(=O)Nc2ccc(-c3ccnc(Cl)c3C#N)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.58
KDR P35968 12/20 0.57
FLT3 P36888 6/20 0.57
KIT P10721 5/20 0.57
FLT1 P17948 5/20 0.57
PDGFRA P16234 4/20 0.57
FLT4 P35916 4/20 0.57
PDGFRB P09619 1/20 0.57
AURKA O14965 4/20 0.55
ROCK2 O75116 4/20 0.55
CSF1R P07333 4/20 0.55
RPS6KB1 P23443 4/20 0.55
AURKB Q96GD4 4/20 0.55
LCK P06239 3/20 0.55
BLK P51451 3/20 0.55
STK3 Q13188 3/20 0.55
ROCK1 Q13464 3/20 0.55
PLK4 O00444 2/20 0.55
PRKD3 O94806 2/20 0.55
MAP4K4 O95819 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703490 0.90 KIT (0.57) CYP3A4KDRFLT3KITFLT1
SCHEMBL3442461 0.89 CYP3A4 (0.60) CYP3A4KDRFLT3KITFLT1
SCHEMBL3443154 0.87 CYP3A4 (0.58) CYP3A4KDRFLT3KITFLT1
SCHEMBL1702802 0.87 KDR (0.57) CYP3A4KDRKITPDGFRAMET
SCHEMBL1703159 0.85 KDR (0.60) KDRFLT3KITFLT1PDGFRA
SCHEMBL1703172 0.84 KDR (0.56) CYP3A4KDRFLT3KITFLT1
SCHEMBL1702911 0.84 KDR (0.60) KDRFLT3KITFLT1PDGFRA
SCHEMBL3443455 0.83 CNR1 (0.52) CYP3A4KDRFLT3KITFLT1
SCHEMBL1703153 0.82 KDR (0.57) CYP3A4KDRFLT3KITFLT1
SCHEMBL1703220 0.81 KDR (0.53) CYP3A4KDRFLT3KITFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 CYP3A4 4186/4885KDR 434/4885FLT3 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.